cSN50.1

cSN50.1 is a synthetic, cell-penetrating peptide that functions as a bifunctional nuclear transport modifier (NTM). It inhibits the nuclear import of proinflammatory stress-responsive transcription factors (SRTFs) such as NF-κB, STATs, and others by targeting importin α5, and also blocks the import of metabolic transcription factors like sterol regulatory element-binding proteins (SREBPs) and carbohydrate response element-binding proteins (ChREBPs) via interaction with importin β1[2][4][8]. By modulating these pathways, cSN50.1 exerts broad-spectrum anti-inflammatory effects and improves lipid homeostasis in preclinical models[2][8]. The drug is being developed primarily for inflammatory skin diseases such as atopic dermatitis (eczema), where it has shown efficacy in reducing inflammation and skin lesions without apparent toxicity[3][8]. It was coinvented by researchers at Vanderbilt University Medical Center and is under development by Amytrx Therapeutics.

Brand names

AMTX-100 CFAMTX100 CFAMTX 100 CF

Other names

NTCInuclear transport checkpoint inhibitorcell-penetrating nuclear transport modifier peptide